Cancer Biomarkers Conference III: Day One 09.15.18
From CME Admins on January 14th, 2019
Since the last Cancer Biomarkers Conference, new tests have emerged for predictive biomarkers used to select cancer patients for new molecular-targeted therapies. New immune therapies for their cancer treatment have also emerged. New technologies, such as liquid biopsy, have advanced. Revised guidelines, as well as new guidelines have also been published. Pathologists and oncologists need to know the answers to a host of questions in this rapidly developing field of biomarkers in order to offer the best patient care.
This activity is designed to provide an in-depth review of complex or uncommon cardiovascular cases.
At the conclusion of this activity, the participant should be able to:
- Distinguish the proper collection, management and submission of pathology specimens for cancer biomarker testing
- State the clinical rationale for patient selection and treatment based on cancer biomarkers
- Describe the most current biomarkers and testing guidelines for multiple solid cancers and hematologic cancers
Physicians, nurses, and residents/fellows will benefit from this course.